Table II.
Association between SPDEF expression and prostate cancer phenotype.
| SPDEF (%) | ||||||
|---|---|---|---|---|---|---|
| Parameters | Number, n | Negative | Weak | Moderate | Strong | P-value |
| All cancer samples | 9,403 | 20.0 | 26.4 | 40.1 | 13.5 | |
| Tumour stagea | <0.0001 | |||||
| pT2 | 5,987 | 22.9 | 27.9 | 37.7 | 11.5 | |
| pT3a | 2,148 | 16.2 | 24.2 | 42.1 | 17.6 | |
| pT3b | 1,179 | 12.6 | 23.7 | 48.1 | 15.6 | |
| pT4 | 53 | 13.2 | 9.4 | 50.9 | 26.4 | |
| Gleason gradea | <0.0001 | |||||
| ≤3+3 | 2,126 | 28.9 | 32.1 | 31.7 | 7.2 | |
| 3+4 | 5,302 | 18.8 | 26.0 | 41.5 | 13.8 | |
| 4+3 | 1,468 | 13.8 | 20.9 | 45.5 | 19.8 | |
| ≥4+4 | 460 | 12.4 | 23.0 | 45.4 | 19.1 | |
| Lymph node metastasisa | <0.0001 | |||||
| N0 | 5,384 | 17.6 | 24.6 | 42.6 | 15.2 | |
| N+ | 560 | 13.0 | 18.6 | 48.6 | 19.8 | |
| Preoperative PSA level (ng/ml)a | 0.0394 | |||||
| <4 | 1,132 | 16.5 | 27.6 | 43.2 | 12.7 | |
| 4–10 | 5,602 | 20.1 | 26.6 | 39.8 | 13.4 | |
| >10–20 | 1,885 | 21.3 | 25.7 | 38.6 | 14.5 | |
| >20 | 676 | 21.0 | 24.1 | 41.6 | 13.3 | |
| Surgical margina | 0.0105 | |||||
| Negative | 7,419 | 20.4 | 26.9 | 39.6 | 13.1 | |
| Positive | 1,811 | 18.2 | 25.1 | 41.9 | 14.9 | |
a
Category with some missing data. The χ2-test was used to calculate P-values. PSA, prostate-specific antigen; SPDEF, SAM pointed domain-containing Ets transcription factor.